Centessa Pharmaceuticals (CNTA) Cash from Investing Activities (2021 - 2026)
Centessa Pharmaceuticals (CNTA) reported Cash from Investing Activities of $42.7 million for Q1 2026, up 119.2% year-over-year from $19.5 million in Q1 2025, and up 119.58% on a QoQ basis from -$218.1 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 6 years of Cash from Investing Activities data on file, last reported at $42.7 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 119.2% year-over-year to $42.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$153.4 million (up 26.19% YoY) and the FY2025 annual result came in at -$418.5 million, down 1438.57% from the prior year.
- Cash from Investing Activities advanced to $42.7 million in Q1 2026 per CNTA's latest filing, from -$218.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $61.9 million in Q3 2025 and bottomed at -$222.4 million in Q1 2025.
- The 5-year median for Cash from Investing Activities is -$240000.0 (2022), against an average of -$27.8 million.
- Peak annual rise in Cash from Investing Activities reached 304512.5% in 2023, while the deepest fall reached 35873.33% in 2023.
- Tracing CNTA's Cash from Investing Activities over 5 years: stood at -$446000.0 in 2022, then slumped by 3997.53% to -$18.3 million in 2023, then surged by 236.8% to $25.0 million in 2024, then sank by 972.54% to -$218.1 million in 2025, then surged by 119.58% to $42.7 million in 2026.
- Per Business Quant, the three latest CNTA Cash from Investing Activities figures stand at $42.7 million (Q1 2026), -$218.1 million (Q4 2025), and $61.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | 42.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.71 Mn |
| Mar 31, 2026 | 42.71 Mn |
| Dec 31, 2025 | -218.13 Mn |
| Dec 31, 2025 | -218.13 Mn |
| Sep 30, 2025 | 61.95 Mn |
| Sep 30, 2025 | 61.95 Mn |
| Jun 30, 2025 | -39.95 Mn |
| Jun 30, 2025 | -39.95 Mn |
| Mar 31, 2025 | -222.39 Mn |
| Mar 31, 2025 | -222.39 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Sep 30, 2024 | 44.96 Mn |
| Sep 30, 2024 | 44.96 Mn |
| Jun 30, 2024 | -55.46 Mn |
| Jun 30, 2024 | -55.46 Mn |
| Mar 31, 2024 | 16.76 Mn |
| Mar 31, 2024 | 16.76 Mn |
| Dec 31, 2023 | -18.28 Mn |
| Dec 31, 2023 | -18.28 Mn |
| Sep 30, 2023 | 48.71 Mn |
| Sep 30, 2023 | 48.71 Mn |
| Jun 30, 2023 | -71.10 Mn |
| Jun 30, 2023 | -71.10 Mn |
| Mar 31, 2023 | -86.34 Mn |
| Mar 31, 2023 | -86.34 Mn |
| Dec 31, 2022 | -446,000.00 |
| Dec 31, 2022 | -446,000.00 |
| Sep 30, 2022 | -16,000.00 |
| Sep 30, 2022 | -16,000.00 |
| Jun 30, 2022 | -229,000.00 |
| Jun 30, 2022 | -229,000.00 |
| Mar 31, 2022 | -240,000.00 |
| Mar 31, 2022 | -240,000.00 |
| Dec 31, 2021 | -64,000.00 |
| Dec 31, 2021 | -64,000.00 |
| Sep 30, 2021 | -48,000.00 |
| Sep 30, 2021 | -48,000.00 |
| Jun 30, 2021 | -149,000.00 |
| Jun 30, 2021 | -149,000.00 |
| Mar 31, 2021 | 63.52 Mn |
| Mar 31, 2021 | 63.52 Mn |